66
Participants
Start Date
May 7, 2019
Primary Completion Date
July 30, 2019
Study Completion Date
December 31, 2019
Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib
Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib
Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
Hospital Ramón y Cajal, Madrid
Instituto Valenciano de Oncologia, Valencia
Hospital da Luz, Lisbon
Hospital Fernando Fonseca, Lisbon
Portuguese Institute of Oncology of Oporto, Porto
Hospital de Jaén, Jaén
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña
H. Vall Hebrón, Barcelona
Hospital del Mar, Barcelona
Hospital Reina Sofia, Córdoba
Onkologikoa, Donostia / San Sebastian
Hospital Arnau de Vilanova, Lleida
Hospital Universitario Virgen del Rocío, Seville
Hospital Arnau de Vilanova de Valencia, Valencia
Hospital Clinico Universitario de Valencia, Valencia
Hospital Miguel Servet, Zaragoza
ICO Badalona, Badalona
ICO l'Hospitalet, L'Hospitalet de Llobregat
Collaborators (1)
Pfizer
INDUSTRY
MedSIR
OTHER